about
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapyGenome-wide association study of susceptibility loci for breast cancer in Sardinian population.Nestin expression associates with poor prognosis and triple negative phenotype in locally advanced (T4) breast cancerLong-term maintenance of prognostic value of survivin and its relationship with p53 in T4 breast cancer patientsTargeting insulin-like growth factor type 1 receptor in cancer therapy.Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia.Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology.Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma.Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (<pCR) after primary chemotherapy.Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers.Treatment of irradiated expanders: protective lipofilling allows immediate prosthetic breast reconstruction in the setting of postoperative radiotherapy.Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.Jejunal obstruction caused by metastasis from an undiagnosed breast cancer: a case report.Hypothyroidism and Thyroid Autoimmunity as a Prognostic Biomarker of Better Response in Metastatic Cancer Long-Term Survivors Treated with Sunitinib.Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis.The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinomaIs It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studySafety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 StudyEverolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyINfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa studyInflammatory breast cancer in Italy: epidemiological and clinical aspectsFamily history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study
P50
Q27851451-B6156E4D-C49E-4A86-97F9-FA3456D7FC1BQ34256001-2A7F36A7-4ABB-43BF-8C85-D05D46CB0C1EQ35615396-D63D0F55-508F-4E64-9168-DD5B735BD712Q35771435-64E871E1-1E4F-4D73-BB08-9E0A81D454EFQ36375382-9AA1F946-7373-4851-89E0-E1E5CA88A4CFQ37624476-535CC27D-97CB-4341-AA20-A040A6D5C55BQ37652666-C758AE7D-E8C3-45E7-9812-962203215D84Q38677321-0250943D-9A1D-4141-B1F2-E656DF7DA2B7Q40492137-60317B27-AB13-4F18-82A7-BF8B512A071DQ40746386-ECCFB388-FF68-4190-A014-B273B8CC4478Q41644108-C7462D2C-BAE3-4F7D-89BD-8FA5A488B7DAQ43246252-E92BF561-1953-446D-8E8E-9E452E243202Q43446697-4C7879C6-973D-496F-9081-F63E070866F6Q45372773-46BFFCE9-3DBB-43DB-B7BB-D61826A7CB48Q47196323-2DED3FC0-CD28-4248-8DC7-88737EB3DF9CQ47639055-F0F805A1-B627-41B6-8E48-C08D34D13D00Q48646811-5DB99D1F-F696-4A1F-B194-10937261C71FQ51323474-574CCD75-6ADD-4C5D-8D7E-933516B3F34CQ53088233-2B9288D6-D2FD-4491-BDF9-8472EDE86D01Q54316815-454B97AD-EA78-410C-8EBE-5AD5EB1BE6DCQ56351538-C9A0A33B-623C-4202-B931-D63027971133Q56383738-D5859C28-2E61-472F-BEBC-FE0934E766EEQ57818329-FF11CE53-D235-4DCF-A245-A2D45DCCB2D4Q58575332-43074BE8-D2DE-4612-9981-AB59547F12DEQ58796910-D8340D84-89BC-4BE9-9674-F41D6AEEBFFBQ62661806-2A2576F3-3B16-4270-9311-2AF79DB7D514Q84303245-E035E365-BD7D-47F5-8233-47B3F07AD3E9Q88122246-9DBD3B3F-888A-40EA-B411-A9F90B9C7F2E
P50
description
researcher ORCID ID = 0000-0002-8211-0363
@en
wetenschapper
@nl
name
Francesco Atzori
@ast
Francesco Atzori
@en
Francesco Atzori
@es
Francesco Atzori
@nl
type
label
Francesco Atzori
@ast
Francesco Atzori
@en
Francesco Atzori
@es
Francesco Atzori
@nl
prefLabel
Francesco Atzori
@ast
Francesco Atzori
@en
Francesco Atzori
@es
Francesco Atzori
@nl
P1153
55375762000
P21
P31
P496
0000-0002-8211-0363